Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

15.40 +0.09 (+0.59%)
Streaming Delayed Price Updated: 1:53 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Polyrizon Ltd. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
From Polyrizon Ltd.
Via GlobeNewswire
TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
Via Investor Brand Network
News headline image
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Provides 2025 and Recent Highlights
Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements 
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
From Polyrizon Ltd.
Via GlobeNewswire
News headline image
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
From Polyrizon Ltd.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.